Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

By V. Subbiah, P. Cassier, S. Siena, E. Garralda, L. Paz-Ares, P. Garrido, E. Nadal, J. Vuky, G. Lopes, G. Kalemkerian and 9 more. 2022